Mainz Biomed announced significant improvements to its ColoAlert product, currently being commercialized across Europe and in select international markets. These updates aim to enhance customer satisfaction and streamline lab operations. ColoAlert is a highly efficacious and easy-to-use, at-home detection test for colorectal cancer. The test utilizes proprietary methods to analyze cell DNA for specific tumor markers combined with the fecal immunochemical test. It is designed to detect tumor DNA and CRC cases in their earliest stages.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYNZ:
- Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
- Mainz Biomed requests breakthrough device designation from FDA for CRC product
- Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
- Mainz Biomed provides half-year corporate update
- Mainz Biomed Provides Half Year 2024 Corporate Update